Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis

This study has been completed.

Study NCT00534794 Information provided by Merck

First Received on September 20, 2007. Last Updated on June 7, 2011 History of Changes

Results First Received: January 30, 2009

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Parallel Assignment; Masking: Double Blind (Subject, Investigator); Primary Purpose: Treatment
Condition:	Allergic Conjunctivitis
Interventions:	Drug: Elestat Drug: Pataday

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Elestat	1 drop each eye for 2 days
Pataday	1 drop each eye for 1 day

Participant Flow: Overall Study

	Elestat	Pataday
STARTED	40	39
COMPLETED	40	39
NOT COMPLETED	0	0

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Elestat	1 drop each eye for 2 days
Pataday	1 drop each eye for 1 day

Baseline Measures

	Elestat	Pataday	Total
Number of Participants [units: participants]	40	39	79
Age [units: years] Mean ± Standard Deviation	41.3 ± 12.18	40.1 ± 13.41	40.7 ± 12.73
Gender [units: participants]
Female	20	27	47
Male	20	12	32

Outcome Measures

Show All Outcome Measures

1. Primary:

Change in Ocular Itch Score From Baseline [ Time Frame: 0 hours, 12 hours ]

Show Outcome Measure 1

2. Secondary:

Ocular Comfort Score at 12 Hours [ Time Frame: 12 hours ]

Show Outcome Measure 2

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: PI cannot publish or discuss trial results until written communication is received from Inspire.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: Saiid Davari – Associate Director, Ophthalmic Clinical Research
Organization: Inspire
phone: 919-941-9777
e-mail: sdavari@inspirepharm.com

No publications provided

Responsible Party:	Inspire Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT00534794 History of Changes
Other Study ID Numbers:	031-408
Study First Received:	September 20, 2007
Results First Received:	January 30, 2009
Last Updated:	June 7, 2011
Health Authority:	United States: Institutional Review Board; United States: Food and Drug Administration